Source: INOVIQ
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US
  • SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers
  • Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests
  • IIQ shares last traded at 86 cents on April 4

INOVIQ (IIQ) has entered into a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US.

SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers.

Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests.

ResearchDx will initially undertake technology transfer, feasibility testing and assay development of the SubB2M-based tests incorporating the SubB2M/CA15.3 test for monitoring breast cancer, the SubB2M/CA125 test for monitoring ovarian cancer and the SubB2M-SPR test for detection of Neu5Gc concentrations.

INOVIQ will pay the agreed costs for the ResearchDx work and related sample, reagent and consumable expenditures.

“As a specialist contract diagnostic organisation with a US-based CAP/CLIA-certified laboratory, ResearchDx is an ideal partner to help progress the development and
commercialisation of our SubB2M-based tests in the US,” INOVIQ CEO Dr Leearne Hinch said.

“This agreement is important as it delivers two milestones in one with ResearchDx providing accredited CRO services and being a potential clinical laboratory partner for SubB2M-based lab developed tests in the US.”

IIQ shares last traded at 86 cents on April 4.

IIQ by the numbers
More From The Market Herald
Ampol (ASX:ALD) - Managing Director & CEO, Matthew Halliday

" Ampol (ASX:ALD) gets all clear for Z Energy (ASX:ZEL) acquisition

Ampol Limited (ASX:ALD) welcomes the decision by the NZCC to provide clearance for its acquisition of…
Ampol Limited,APL - Managing Director and CEO Matthew Halliday

" Ampol (ASX:ALD) sells 20 retail sites for $48m in net proceeds

Ampol Limited (APL) announces the sale of 20 care freehold convenience retail sites to Charter Hall…

" Zenith Minerals (ASX:ZNC) begins drilling at Waratah Well

Zenith Minerals (ASX:ZNC) has begun drilling at the Waratah Well lithium project in Western Australia.
Resource Base (ASX:RBX) - Executive Chairman & CEO, Shannon Green

" Resource Base (ASX:RBX) makes significant REE discovery at Mitre Hill

Resource Base (ASX:RBX) has made a significant rare earth element (REE) discovery at its Mitre Hill…